Prevalence and risk factors associated with decompensated heart failure after successful elective cardioversion for atrial fibrillation and atrial flutter

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Christina Healy, Palwinder Sodhi, Annabelle Barnett, Timothy Hess, Jennifer M. Wright
{"title":"Prevalence and risk factors associated with decompensated heart failure after successful elective cardioversion for atrial fibrillation and atrial flutter","authors":"Christina Healy,&nbsp;Palwinder Sodhi,&nbsp;Annabelle Barnett,&nbsp;Timothy Hess,&nbsp;Jennifer M. Wright","doi":"10.1016/j.ahjo.2024.100480","DOIUrl":null,"url":null,"abstract":"<div><h3>Study objective</h3><div>To determine the incidence of and risk factors for HF after successful electrical and ablative cardioversion (CV) of atrial fibrillation (AF) and atrial flutter (AFL).</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Setting</h3><div>Single center academic institution.</div></div><div><h3>Participants</h3><div>Seven hundred fifty-five patients underwent successful elective CV from July 1, 2018 to May 20, 2019. Patients presenting in arrhythmias other than AF or AFL, those who developed HF due to alternative etiologies, and those who developed arrhythmia recurrence within 30 days were excluded. Medical records of the remaining 451 patients were reviewed before and after CV.</div></div><div><h3>Main outcomes measured</h3><div>Development of heart failure despite sinus rhythm following CV and the risk factors associated with this outcome.</div></div><div><h3>Results</h3><div>Thirty-three (7.3 %) of 451 patients who met inclusion criteria for our study developed new or worsening HF symptoms while maintaining sinus rhythm (SR) after successful CV. Symptoms were reported an average of 5.1 days following CV (range 0–17 days, SD 4.71). Following a multivariate stepwise logistic regression model, prior HF hospitalization (OR 3.91, 95 % CI 1.82–8.39), BMI (OR 1.06, 95 % CI 1.02–1.11), and valve disease (OR 2.51, 95 % CI 1.12–5.60) remained significant risk factors, and anti-arrhythmic drug (AAD) use was marginally significant (OR 2.02, 95 % CI 0.95–4.31).</div></div><div><h3>Conclusion</h3><div>Despite maintenance of SR, 7.3 % of patients developed decompensated HF in the 30 days following successful CV of AF or AFL, indicating this complication may be more frequent than previously believed. Predictors of HF post-CV included elevated BMI, valve disease, previous HF hospitalization, and prior AAD use.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"47 ","pages":"Article 100480"},"PeriodicalIF":1.3000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American heart journal plus : cardiology research and practice","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266660222400123X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Study objective

To determine the incidence of and risk factors for HF after successful electrical and ablative cardioversion (CV) of atrial fibrillation (AF) and atrial flutter (AFL).

Design

Retrospective cohort study.

Setting

Single center academic institution.

Participants

Seven hundred fifty-five patients underwent successful elective CV from July 1, 2018 to May 20, 2019. Patients presenting in arrhythmias other than AF or AFL, those who developed HF due to alternative etiologies, and those who developed arrhythmia recurrence within 30 days were excluded. Medical records of the remaining 451 patients were reviewed before and after CV.

Main outcomes measured

Development of heart failure despite sinus rhythm following CV and the risk factors associated with this outcome.

Results

Thirty-three (7.3 %) of 451 patients who met inclusion criteria for our study developed new or worsening HF symptoms while maintaining sinus rhythm (SR) after successful CV. Symptoms were reported an average of 5.1 days following CV (range 0–17 days, SD 4.71). Following a multivariate stepwise logistic regression model, prior HF hospitalization (OR 3.91, 95 % CI 1.82–8.39), BMI (OR 1.06, 95 % CI 1.02–1.11), and valve disease (OR 2.51, 95 % CI 1.12–5.60) remained significant risk factors, and anti-arrhythmic drug (AAD) use was marginally significant (OR 2.02, 95 % CI 0.95–4.31).

Conclusion

Despite maintenance of SR, 7.3 % of patients developed decompensated HF in the 30 days following successful CV of AF or AFL, indicating this complication may be more frequent than previously believed. Predictors of HF post-CV included elevated BMI, valve disease, previous HF hospitalization, and prior AAD use.
成功进行心房颤动和心房扑动选择性心脏复律术后出现失代偿性心力衰竭的患病率和相关风险因素
研究目的确定房颤(AF)和心房扑动(AFL)成功电复律和消融心脏复律(CV)后高血压的发生率和风险因素.设计回顾性队列研究.设置单中心学术机构.参与者2018年7月1日至2019年5月20日期间,755名患者成功接受了选择性CV。排除了出现房颤或AFL以外的心律失常的患者、因其他病因导致HF的患者以及30天内心律失常复发的患者。对其余 451 名患者进行了心电图检查前后的病历回顾。主要测量结果心电图检查后虽有窦性心律,但仍出现心力衰竭,以及与这一结果相关的风险因素。出现症状的时间平均为 CV 后 5.1 天(范围为 0-17 天,SD 为 4.71)。在多变量逐步逻辑回归模型中,之前的高血压住院治疗(OR 3.91,95 % CI 1.82-8.39)、体重指数(OR 1.06,95 % CI 1.02-1.11)和瓣膜疾病(OR 2.51,95 % CI 1.12-5.60)仍然是重要的风险因素,而使用抗心律失常药物(AAD)则略有意义(OR 2.结论尽管维持了 SR,但仍有 7.3% 的患者在房颤或 AFL 成功 CV 后的 30 天内出现失代偿性 HF,这表明这种并发症可能比之前认为的更为常见。心房颤动后出现心房颤动的预测因素包括体重指数升高、瓣膜疾病、既往心房颤动住院和既往使用过 AAD。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
0
审稿时长
59 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信